Broadwing Bio is focused on developing innovative antibody therapies aimed at treating significant causes of adult vision loss, particularly Geographic Atrophy (GA) and Glaucoma. The company employs a genetics-driven approach, utilizing insights from naturally occurring genetic variants to identify and validate targets for their therapies. This strategy is designed to halt or slow the progression of vision loss associated with these conditions, thereby preserving patients' sight and improving their quality of life. Broadwing Bio's commitment to advancing its pipeline is underscored by its collaboration with industry leaders, leveraging expertise in antibody discovery and development to maximize therapeutic benefits.

The team at Broadwing Bio comprises experienced professionals with a strong background in molecular biology and drug development, including former leaders from renowned organizations like Genentech and Stanford University. Their collective expertise enables Broadwing to focus on creating effective treatments for ocular diseases, particularly those that currently lack viable options. By fostering partnerships and engaging in collaborative efforts, Broadwing Bio aims to accelerate the delivery of its therapies to patients in need, ultimately working towards the mission of ending blindness.

United States

Broadwing Bio is advancing antibody therapies to treat common causes of vision loss. Focused on genetically validated targets, our goal is to develop best-in-disease therapies to meaningfully preserve eyesight for glaucoma and geographic atrophy patients.

Broadwing Bio

Company Details